Breakthrough pancreatic cancer pill is ‘closest thing to a cure’ - The Telegraph

Direct Source Verification: This story is aggregated from The Telegraph (telegraph.co.uk). Full reporting rights and copyright belong to the primary publisher.
Pancreatic cancer is one of the most deadly forms of the disease Credit: Science Photo Library RF/Sebastian Kaulitzki Laura Donnelly Health Editor Show biography Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK...

Pancreatic cancer is one of the most deadly forms of the disease Credit: Science Photo Library RF/Sebastian Kaulitzki Laura Donnelly Health Editor Show biography Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

A daily pill has raised hopes of a cure for one of the deadliest cancers after after patients receiving the treatment saw their tumours disappear.

One in 12 patients with advanced pancreatic cancer, often called a “silent killer”, had no detectable tumours after taking the daraxonrasib pill alongside chemotherapy.

Dr Wungki Park, who presented the findings on the drug, said he had never seen so many tumours disappear in patients whose cancer had spread. “This is the closest to cure,” he said.

Half of all people diagnosed with pancreatic cancer die within three months. Among those whose cancer has spread to other organs, only about 3 per cent survive for five years.

Scans of a patient before (left) and after treatment with daraxonrasib and chemotherapy show that tumours are no longer visible Credit: Dr Michael May/Dr Wungki Park/Memorial Sloan Kettering Cancer Center Michelle Mitchell, the chief executive of Cancer Research UK, described the pill as “the biggest leap forward we’ve seen in decades for pancreatic cancer patients”.

More than 11,000 people are diagnosed with pancreatic cancer in the UK each year and more than 10,000 die from it.

The pill targets a protein called KRAS, nicknamed the “Death Star” because it is so difficult to attack with drugs. More than nine in 10 pancreatic tumours carry a mutation in the gene that makes KRAS.

The mutation causes the protein to send signals telling cancer cells to keep growing. But daraxonrasib binds to the protein and blocks those signals.

Earlier findings on the pill, which found it doubled average life expectancy, moved medics to tears.

Dr Rachna Shroff, a gastrointestinal cancer specialist at the University of Arizona, said she “started crying in the clinic” when she read the results.

That trial involved about 500 patients whose pancreatic cancer had spread and who had already received standard treatment. Those given daraxonrasib lived almost twice as long as those on chemotherapy, with median survival of 13.2 months against 6.7 months.

The latest trial tested what happened when patients received the pill and chemotherapy together.

Dr Park presented the findings at the EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics in Barcelona.

The tumours in five of the 61 patients in the study disappeared. In all, tumours shrank or disappeared in 60.7 per cent of patients, and the treatment held the disease in check in 90.2 per cent.

“In about one in 12 patients, it completely disappeared,” said Dr Park, an oncologist at Memorial Sloan Kettering Cancer Centre in New York.

“And then with such a long follow-up, this is real. We’ve never seen such a thing.”

Researchers followed patients for a median period of 18 months. Doctors call the disappearance of all detectable tumours a complete response. It is too early to tell whether the cancer will return in those five patients.

A year after starting treatment, 76.6 per cent of patients were still alive.

Typically, about 40 to 45 per cent of those given chemotherapy alone survive a year.

The early trial had no chemotherapy-only group against which to measure the benefit of adding the pill. Half the patients lived at least 12.8 months without their cancer getting worse.

A phase-three international trial is now recruiting.

Dr Madina Kara, the head of research at Pancreatic Cancer UK, said patients’ loved ones “would give anything to spend more precious time with them”.

She urged ministers to increase investment so more patients could take part in trials and ensure that any drugs proven to work reach patients across the UK quickly.

Ms Mitchell said more trials were needed before the treatment could be assessed for NHS use. Researchers also needed to establish how best to combine the drug with other therapies.

Original Source
https://www.telegraph.co.uk/news/2026/11/20/breakthrough-pancreatic-cancer-pill-closest-thing-cure/
Visit The Telegraph ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health